Due to the lack of progesterone receptor (PR), estrogen receptor (ER) and HER2 expression, triple negative breast cancer patients may not profit from endocrine and trastuzumab therapy, but require targeted drugs, antibody-drug conjugates, or immunotherapy, especially in advanced tumor stages [4]. This evidence concerns the gene ESR1 and neoplasm.